Also, if they get 20% of the hospitals after 1 year, the multiple will drop from 10 since they can't get 200% - unless they wear out after a few years. If it takes 3 years to get 20% and the machines last 10 years (like other sterilizers in the OR or central storage which is a totally different space and machine), investors MIGHT think 20% is all the hospital market they will get, so mzei might not get much of any multiple on US hospital earnings unless the machines wear out every year or so.
There are a lot of market wildcards with this potentially disruptive tech that no one can factor in today - No way anyone will buyout this company for a decent buck until sales are proven - Based on the Cdn hospital going MRSA free for 8 months after a sterilization this device may have room to be priced higher, or might have to be marketed as a contract cleaning job if hospitals just want it around for outbreaks. UV is practically zero opex so it could still survive in the market with flareups handled on contract by MZEI - who knows what cost benefit studies will come up with?
Another big factor is US healthcare has big litigation but in Canada not much - ir told me it is a tough sell in Canada, especially if they fix the problem for long periods of time - might have to be contract killing for places like Canada, where I am from.
AI
